RxDoctor Payments Data

Tsung Mou

Urogynecology and Reconstructive Pelvic Surgery · Boston, MANPI 1235524752

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Intuitive Surgical at 54.8% of the total. Reporting peaked in 2023 at $7,021 and has fallen 97.5% since, to $175 in 2025.

$9,760in general payments, 2019–2025

Across 53 payments — averaging $184.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Axonics, Inc.$3K
  • Boston Scientific$650
  • AbbVie$224
  • Medtronic$181
  • Coloplast$118
  • plus $296 from 7 others

What the payments were for

  • Speaking & faculty fees$4,00041%
  • Travel & lodging$2,35724%
  • Food & beverage$2,33324%
  • Education$1,07011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,760 in reported general payments places this provider in the 70th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.

See all urogynecology and reconstructive pelvic surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$53,679
Medicare patients
61
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron24$26,391
Estradiol56$3,503
Clobetasol Propionate19$532
Ibuprofen33$161
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$118
Tramadol Hcl34$46
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$38

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →